Remedy Meds GLP-1: Program Structure and Options

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Remedy Meds or its parent company, and no affiliate links or paid placement are involved.

Remedy Meds pairs a telehealth clinic with a compounded pharmacy, and its GLP-1 offering is the core of what it does. This review maps that offering end to end — how the intake quiz leads to a prescription, which compounds move through the model, and what the evidence behind them shows. It is fair-balance context, not a buying recommendation, current as of July 2026.

Remedy Meds’ GLP-1 offering at a glance

Unlike programs that bolt a GLP-1 add-on onto another specialty, Remedy Meds is built around compounded GLP-1 therapy from the start. A program in this model delivers a virtual clinical evaluation by a licensed provider, a written prescription, and ongoing follow-up, with fulfillment leaning on a 503A compounding pharmacy. Current program structure is published at Remedy Meds’s official website.

From intake quiz to dispensed compound

Access begins with an intake quiz covering weight, medical history, and current medications. A licensed clinician reviews it and, if you meet eligibility, issues a prescription, which is then routed to a compounding pharmacy for fulfillment; follow-up visits support dose titration and side-effect management. One practical consequence of the quiz-first design is pricing visibility: As of the July 2026 capture, the only price Remedy publishes openly is a microdose tier at $189 per month (compounded semaglutide or tirzepatide); standard-dose pricing appears only after its intake quiz.

Compounded semaglutide and tirzepatide in this model

The compounds fall into two pharmacology groups: GLP-1 receptor agonists such as semaglutide, and the GIP/GLP-1 dual agonist tirzepatide. Remedy’s model centers on compounded versions of these — prepared by a 503A pharmacy for an individual prescription — rather than branded retail products. Compounded medications are not FDA-approved the way branded drugs are, so it is worth confirming exactly what you are prescribed.

The trial evidence behind the compound class

The clinical foundation is well defined. STEP evaluated semaglutide for weight management (The New England Journal of Medicine, 2021); SURMOUNT evaluated tirzepatide for weight management (NEJM 2022); and SURMOUNT-OSA evaluated tirzepatide for obstructive sleep apnea (NEJM 2024). Trial populations and endpoints vary, and individual outcomes differ from the averages those studies report.

The genetic architecture under the GLP-1 response

A prescription captures eligibility, not the genetic terrain your metabolism starts from. Variants in FTO, GLP1R (the receptor these compounds target), MC4R (central to satiety and energy balance), and TCF7L2 (tied to glucose homeostasis and GLP-1 secretion) map that baseline. They are pathway-level and do not predict response to any specific compound. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across those genes, adding context a telehealth prescription alone does not provide.

PlexusDx offers the same active compounds through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — paired with the pathway profile in a test before you invest model.

Not affiliated: PlexusDx is not affiliated with Remedy Meds and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This article is educational. PlexusDx is not affiliated with Remedy Meds and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols, or start upstream and take the Precision Peptide Genetic Test to map your GLP-1 pathway first.

Frequently Asked Questions About the Remedy Meds GLP-1 Program

What GLP-1 medications does Remedy Meds offer?

Remedy’s model centers on compounded semaglutide and tirzepatide, prepared by a 503A pharmacy for an individual prescription. The exact options depend on clinical eligibility determined during intake, so complete the quiz on the brand’s own site to see what a licensed provider approves for you.

Do I have to take the intake quiz to get started?

Yes. The quiz gathers your weight, medical history, and medications so a licensed clinician can assess eligibility, and it is also where standard-dose pricing is revealed. Only the microdose tier at $189 per month is shown before you complete it.

Is compounded GLP-1 medication FDA-approved?

Compounded semaglutide and tirzepatide are prepared through a 503A compounding pathway and are not FDA-approved the way branded products are. It is a recognized route, but the regulatory status differs, so it is reasonable to confirm which version you receive and why.

What does the Precision Peptide Genetic Test add here?

It does not predict response to any compound. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 to describe your baseline appetite-regulation and energy-balance biology, giving you and your provider genetic context that a GLP-1 prescription alone does not capture.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.